CA2860289C - Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections - Google Patents

Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections Download PDF

Info

Publication number
CA2860289C
CA2860289C CA2860289A CA2860289A CA2860289C CA 2860289 C CA2860289 C CA 2860289C CA 2860289 A CA2860289 A CA 2860289A CA 2860289 A CA2860289 A CA 2860289A CA 2860289 C CA2860289 C CA 2860289C
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2860289A
Other languages
English (en)
French (fr)
Other versions
CA2860289A1 (en
Inventor
Leonid Beigelman
Guangyi Wang
David Bernard Smith
Jerome Deval
Marija Prhavc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biopharma Inc
Original Assignee
Janssen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2860289(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biopharma Inc filed Critical Janssen Biopharma Inc
Priority to CA3107640A priority Critical patent/CA3107640A1/en
Publication of CA2860289A1 publication Critical patent/CA2860289A1/en
Application granted granted Critical
Publication of CA2860289C publication Critical patent/CA2860289C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Package Frames And Binding Bands (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
CA2860289A 2011-12-22 2012-12-20 Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections Active CA2860289C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3107640A CA3107640A1 (en) 2011-12-22 2012-12-20 Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579560P 2011-12-22 2011-12-22
US61/579,560 2011-12-22
US201261613836P 2012-03-21 2012-03-21
US61/613,836 2012-03-21
PCT/US2012/071063 WO2013096679A1 (en) 2011-12-22 2012-12-20 Substituted nucleosides, nucleotides and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3107640A Division CA3107640A1 (en) 2011-12-22 2012-12-20 Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections

Publications (2)

Publication Number Publication Date
CA2860289A1 CA2860289A1 (en) 2013-06-27
CA2860289C true CA2860289C (en) 2021-03-16

Family

ID=48669505

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2860289A Active CA2860289C (en) 2011-12-22 2012-12-20 Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections
CA3107640A Abandoned CA3107640A1 (en) 2011-12-22 2012-12-20 Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3107640A Abandoned CA3107640A1 (en) 2011-12-22 2012-12-20 Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections

Country Status (36)

Country Link
US (4) US9073960B2 (cg-RX-API-DMAC7.html)
EP (2) EP2794627B1 (cg-RX-API-DMAC7.html)
JP (2) JP6385825B2 (cg-RX-API-DMAC7.html)
KR (1) KR102072041B1 (cg-RX-API-DMAC7.html)
CN (2) CN107459544B (cg-RX-API-DMAC7.html)
AP (1) AP2014007796A0 (cg-RX-API-DMAC7.html)
AR (1) AR089408A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012358803C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014014740B1 (cg-RX-API-DMAC7.html)
CA (2) CA2860289C (cg-RX-API-DMAC7.html)
CL (1) CL2014001641A1 (cg-RX-API-DMAC7.html)
CO (1) CO6990737A2 (cg-RX-API-DMAC7.html)
CY (1) CY1121416T1 (cg-RX-API-DMAC7.html)
DK (1) DK2794627T3 (cg-RX-API-DMAC7.html)
EA (1) EA035493B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14010277A (cg-RX-API-DMAC7.html)
ES (1) ES2702060T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166496B (cg-RX-API-DMAC7.html)
HK (2) HK1203204A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20182096T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041509T2 (cg-RX-API-DMAC7.html)
IL (2) IL233152B (cg-RX-API-DMAC7.html)
LT (1) LT2794627T (cg-RX-API-DMAC7.html)
MX (2) MX356509B (cg-RX-API-DMAC7.html)
PH (2) PH12014501436B1 (cg-RX-API-DMAC7.html)
PL (1) PL2794627T3 (cg-RX-API-DMAC7.html)
PT (1) PT2794627T (cg-RX-API-DMAC7.html)
RS (1) RS58099B1 (cg-RX-API-DMAC7.html)
SG (3) SG11201402826YA (cg-RX-API-DMAC7.html)
SI (1) SI2794627T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800662T1 (cg-RX-API-DMAC7.html)
TW (1) TWI659963B (cg-RX-API-DMAC7.html)
UA (1) UA117095C2 (cg-RX-API-DMAC7.html)
UY (1) UY34536A (cg-RX-API-DMAC7.html)
WO (1) WO2013096679A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404486B (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US8772474B2 (en) 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2827875T (pt) * 2012-03-21 2019-02-11 Janssen Biopharma Inc Nucleósidos substituídos, nucleótidos e análogos dos mesmos
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
HK1216535A1 (zh) 2012-12-21 2016-11-18 Alios Biopharma, Inc. 取代的核苷、核苷酸及其類似物
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
AR099632A1 (es) 2013-04-05 2016-08-10 Alios Biopharma Inc Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
WO2014209979A1 (en) 2013-06-26 2014-12-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015031763A2 (pt) 2013-06-26 2017-08-29 Alios Biopharma Inc Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
US10435430B2 (en) 2013-07-31 2019-10-08 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
US20160271160A1 (en) 2013-10-17 2016-09-22 Medivir Ab Hcv polymerase inhibitors
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
KR102327464B1 (ko) 2014-02-06 2021-11-16 리보사이언스 엘엘씨 인플루엔자 rna 복제의 저해제로서의 4'-다이플루오로메틸 치환된 뉴클레오사이드 유도체
JP6191989B2 (ja) * 2014-02-12 2017-09-06 学校法人東京理科大学 アデニン誘導体又はその薬理学的に許容しうる塩、その製造方法、及びその用途
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN106573011A (zh) 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
EP3171878A4 (en) * 2014-07-22 2018-03-14 Alios Biopharma, Inc. Methods for treating paramyxoviruses
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
AU2015301334A1 (en) * 2014-08-05 2017-02-23 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
TWI673283B (zh) * 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
US10358458B2 (en) * 2014-09-26 2019-07-23 Riboscience Llc 4′-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication
EP3204121B1 (en) * 2014-10-08 2019-06-19 Epigenetics Pharma LLC Silylated 5-aza-pyrimidine prodrugs useful for treating cancer
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
HK1246780A1 (zh) 2015-03-11 2018-09-14 Janssen Biopharma, Inc. 氮杂-吡啶酮化合物及其用途
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN107501247A (zh) * 2016-06-14 2017-12-22 安徽贝克联合制药有限公司 一种尿嘧啶核苷类衍生物的制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
JP2019524795A (ja) 2016-08-12 2019-09-05 ヤンセン バイオファーマ インク． 置換ヌクレオシド、ヌクレオチド、及びそのアナログ
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
EP3661513A4 (en) 2017-07-31 2021-07-14 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
AU2018386222B2 (en) * 2017-12-15 2023-04-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
CR20210460A (es) 2019-03-06 2022-02-03 Glaxosmithkline Ip No 2 Ltd Compuestos útiles en la terapia del vih
WO2021011572A1 (en) * 2019-07-18 2021-01-21 The Board Of Trustees Of The Leland Stanford Junior University Enhancing the antiviral efficacy of rna virus inhibition by combination with modulators of pyrimidine metabolism
US11708637B2 (en) * 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021195011A1 (en) * 2020-03-24 2021-09-30 Intrinsic Medicine, Inc. Immunomodulatory oligosaccharides for the treatment of viral respiratory infection
CN111892636A (zh) * 2020-08-07 2020-11-06 山东大学 一种阿兹夫定的合成方法
ES3015457T3 (en) 2020-08-24 2025-05-05 Gilead Sciences Inc Phospholipid compounds and uses thereof
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4493573A1 (en) 2022-03-15 2025-01-22 Rome Therapeutics, Inc. Compounds and methods for treating disease
WO2024015916A2 (en) * 2022-07-13 2024-01-18 Thomas Jefferson University 4'-alkyne-2'-deoxycytidine-based compounds and anti-cancer uses thereof
WO2024159117A1 (en) * 2023-01-26 2024-08-02 The Regents Of The University Of California Antiviral prodrugs, intermediate-and long-acting formulations, and methods
CN116425703B (zh) * 2023-03-27 2024-05-31 浙大宁波理工学院 一种饱和环醚类化合物c2位环外甲基氘代的方法

Family Cites Families (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH563405A5 (cg-RX-API-DMAC7.html) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
IL51342A (en) 1977-01-27 1980-11-30 Abic Ltd Ethoxyquin derivatives,their preparation and pharmaceutical and veterinary compositions comprising them
US4230698A (en) 1978-05-12 1980-10-28 Research Corporation 2-Substituted arabinofuranosyl nucleosides and nucleotides
US4211773A (en) 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
AU5118979A (en) 1978-10-16 1980-04-24 Takeda Chemical Industries Ltd. 2,6-diaminoebularines
US4652554A (en) 1982-02-22 1987-03-24 St. Jude Children's Research Hospital Nitro-substituted 1-β-D-arabinofuranosylcytosines
JPS60228497A (ja) 1984-04-27 1985-11-13 Sumitomo Chem Co Ltd 新規なアデニル酸誘導体
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
US4626526A (en) 1984-10-26 1986-12-02 Warner-Lambert Company (S)-N6 -2-hydroxypropyladenosines
US4855304A (en) 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
JPS61219478A (ja) 1985-03-26 1986-09-29 Potsupuribetsuto Fastener Kk 溶接検知方法及び装置
PL144471B1 (en) 1985-04-22 1988-05-31 Polska Akad Nauk Centrum Method of obtaining novel 3',5'-cyclic adensine dithiophosphate
US4762823A (en) 1985-10-16 1988-08-09 Sloan-Kettering Institute For Cancer Research Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil
US4797495A (en) 1985-11-22 1989-01-10 Burroughs Wellcome Co. Benzo[c]carbazole propanediol compound and salts thereof
GR870593B (en) 1986-04-14 1987-08-14 Shell Int Research Halogenated heterocyclic ether herbicides
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
SU1417408A1 (ru) 1986-12-02 1995-09-10 Г.П. Акулов Способ получения меченного тритием дезоксиаденозина
JPH0699467B2 (ja) 1987-03-04 1994-12-07 ヤマサ醤油株式会社 ２▲’▼−デオキシ−２▲’▼（ｓ）−アルキルピリミジンヌクレオシド誘導体
CA1340032C (en) 1987-06-24 1998-09-08 Jim Haralambidis Lucleoside derivatives
DE3730542A1 (de) 1987-09-11 1989-04-06 Hoechst Ag Arzneimittel mit einem gehalt an bestimmten 6-mercaptopurin-derivaten, verwendung dieser 6-mercaptopurin-derivate, verfahren zur herstellung der arzneimittel sowie einige neue 6-mercaptopurin-derivate und verfahren zu deren herstellung
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
HU204843B (en) 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
MX9203459A (es) 1988-11-15 1992-08-01 Merrell Pharma Inc Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
US5616702A (en) 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives
CA2002648C (en) 1988-11-15 2000-02-29 James R. Mccarthy 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
PH27609A (en) 1988-11-21 1993-08-31 Syntex Inc Antiviral agents
SE462497B (sv) 1988-11-30 1990-07-02 Clas Fredrik Runesson Kaelland Saett foer att aktivitetsbestaemma polymeraser
FR2642074B1 (fr) 1989-01-20 1994-04-29 Oris Ind Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide
US5296348A (en) 1989-05-16 1994-03-22 The Wistar Institute Of Anatomy And Biology Methods for screening monoclonal antibodies for therapeutic use
DE3916871A1 (de) 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
DE3924424A1 (de) 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
JPH0699711B2 (ja) 1989-07-25 1994-12-07 花王株式会社 液体洗浄剤組成物
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
JPH05504552A (ja) 1989-10-24 1993-07-15 ギリアド　サイエンシズ，インコーポレイテッド ２’位が改変されたオリゴヌクレオチド
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5514786A (en) 1990-01-11 1996-05-07 Isis Pharmaceuticals, Inc. Compositions for inhibiting RNA activity
AU651569B2 (en) 1990-01-11 1994-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating RNA activity and gene expression
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
CA2037767A1 (en) 1990-03-23 1991-09-24 Mark D. Wittman Conversion of amines to hydroxylamines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5478813A (en) 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
AU7623991A (en) 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
GB9012899D0 (en) 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
JP2559917B2 (ja) 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5777100A (en) 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99125A0 (en) 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5420115A (en) * 1990-09-10 1995-05-30 Burroughs Wellcome Co. Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO1992012718A1 (en) 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
US5171849A (en) 1991-04-19 1992-12-15 The Ohio State University Research Foundation 2' and 3' Carboranyl uridines and their diethyl ether adducts
US5446031A (en) 1991-04-24 1995-08-29 Yamasa Shuyu Kabushiki Kaisha 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives
GB9111580D0 (en) 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5192764A (en) 1991-05-30 1993-03-09 Research Foundation Of State Of N.Y. Pyrazinone n-oxide nucleosides and analogs thereof
US5508407A (en) 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
JPH0551395A (ja) 1991-08-21 1993-03-02 Teijin Ltd ペンタフルオロプロピオニル化（デオキシ）ウリジンおよびそれを用いる（デオキシ）ウリジンの測定方法
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE4131579A1 (de) 1991-09-23 1993-03-25 Boehringer Mannheim Gmbh Thiadiazolo(4,3-a)pyridinderivate, verfahren zu ihrer herstellung und diese enthaltenden arzneimittel
CA2079413C (en) 1991-09-30 2003-09-09 Masakatsu Kaneko Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
EP0637965B1 (en) 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
FR2684997A1 (fr) 1991-12-12 1993-06-18 Centre Nat Rech Scient Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.
FR2688003B1 (fr) 1992-02-28 1995-06-30 Univ Limoges Derives de nucleosides, leur preparation et leurs applications biologiques.
US5543507A (en) 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
ES2123642T3 (es) 1992-04-10 1999-01-16 Merrell Pharma Inc Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5808139A (en) 1992-04-21 1998-09-15 Ligand Pharmaceuticals Incorporated Non-steroid progesterone receptor agonist and antagonist and compounds and methods
DK0640092T3 (da) 1992-05-12 1996-12-30 Merrell Pharma Inc Fremgangsmåde til fremstilling af ribonucleotid-reduktaseinhibitorer
DE4217679C2 (de) 1992-05-26 1998-02-19 Genieser Hans Gottfried Dr Cyclische Guanosin-3',5'-phosphorothioat-Derivate
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
AU4684993A (en) 1992-07-23 1994-02-14 Isis Pharmaceuticals, Inc. Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
CA2159632A1 (en) 1993-03-31 1994-10-13 Ashis Kumar Saha Novel 5'-substituted nucleosides and oligomers produced therefrom
BR9407510A (pt) 1993-09-17 1997-01-07 Gilead Sciences Inc Análogos de nucleotideo
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
JPH07242544A (ja) 1994-03-01 1995-09-19 Takeda Chem Ind Ltd 抗腫瘍剤
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
US6004939A (en) 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
PT879056E (pt) 1996-01-23 2002-10-31 Ribapharm Inc Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
JPH09328497A (ja) * 1996-04-12 1997-12-22 Yamasa Shoyu Co Ltd ４’−フルオロメチルヌクレオシド
HUP0001107A3 (en) 1996-10-16 2003-01-28 Icn Pharmaceuticals Inc Costa Monocyclic l-nucleosides, analogs and pharmaceutical compositions thereof
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
US20030064945A1 (en) 1997-01-31 2003-04-03 Saghir Akhtar Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP2253639A1 (en) * 1997-09-12 2010-11-24 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
WO1999061583A2 (en) 1998-05-28 1999-12-02 Incara Pharmaceuticals Corp. Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction
DE19855963A1 (de) 1998-12-04 2000-06-08 Herbert Schott Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2368135C (en) * 1999-03-18 2010-06-08 Exiqon A/S Xylo-lna analogues
CN102180924A (zh) 1999-05-04 2011-09-14 桑塔里斯制药公司 L-核糖-lna类似物
AU4431200A (en) 1999-05-12 2000-12-05 Yamasa Corporation 4'-c-ethynyl pyrimidine nucleosides
JP4076114B2 (ja) 1999-05-12 2008-04-16 ヤマサ醤油株式会社 ４’−ｃ−エチニルプリンヌクレオシド化合物
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
CA2381297A1 (en) 1999-08-27 2001-04-19 Esmir Gunic Pyrrolo¬2,3-d|pyrimidine nucleoside analogs
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU1929801A (en) 1999-12-16 2001-06-25 Alcon Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
JP2002322192A (ja) * 2000-08-10 2002-11-08 Sankyo Co Ltd ２’−ｏ，４’−ｃ−架橋ヌクレオシドトリリン酸体
WO2002031176A1 (fr) 2000-10-12 2002-04-18 Mitsui Chemicals, Inc. Procédé permettant la production de nucléosides
JP2004313002A (ja) 2000-10-12 2004-11-11 Mitsui Chemicals Inc ヌクレオシドの製造方法
DK2251015T3 (da) * 2000-10-18 2013-05-13 Gilead Pharmasset Llc Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
JP4012070B2 (ja) 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
ATE526339T1 (de) 2001-01-22 2011-10-15 Merck Sharp & Dohme Nukleosidderivate als inhibitoren der rna- abhängigen viralen rna-polymerase
JP2002302498A (ja) 2001-04-03 2002-10-18 Mitsui Chemicals Inc ヌクレオシドの工業的な製造法
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2003070912A2 (en) 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1390472A4 (en) 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
JP2003012690A (ja) 2001-07-03 2003-01-15 Mitsui Chemicals Inc 置換イミダゾール誘導体又は置換ベンズイミダゾール誘導体を用いたヌクレオチドの製造法
JP2003055392A (ja) 2001-08-08 2003-02-26 Mitsui Chemicals Inc １−リン酸化糖の製造法並びにヌクレオシドの製造法
CA2456292A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7125982B1 (en) 2001-12-05 2006-10-24 Frayne Consultants Microbial production of nuclease resistant DNA, RNA, and oligo mixtures
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US20070032448A1 (en) * 2002-01-17 2007-02-08 Zhi Hong Sugar modified nucleosides as viral replication inhibitors
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
US7285658B2 (en) * 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
JP2003310293A (ja) 2002-04-26 2003-11-05 Mitsui Chemicals Inc ヌクレオシド化合物の製造法
ES2290448T3 (es) 2002-05-08 2008-02-16 Santaris Pharma A/S Sistesis de derivados de acidos nucleicos bloqueados.
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US20040014957A1 (en) 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
EP1511757B1 (en) 2002-06-07 2015-11-04 Universitair Medisch Centrum Utrecht New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
RS114104A (sr) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, 2'i 3'-nukleozidni prolekovi za lečenje flaviviridae infekcija
EP1523489B1 (en) 2002-06-28 2014-03-12 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7393954B2 (en) 2002-12-12 2008-07-01 Reliable Biopharmaceutical Corporation Process for the production of pentostatin aglycone and pentostatin
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
US7002006B2 (en) 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
CN1777432B (zh) 2003-02-19 2011-06-08 耶鲁大学 用于hiv感染的抗病毒核苷类似物
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ATE486883T1 (de) 2003-08-27 2010-11-15 Biota Scient Management Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
EA009670B1 (ru) 2003-09-18 2008-02-28 Ай Эс Ай Эс ФАРМАСЬЮТИКАЛЗ, ИНК. МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
EP1670755A4 (en) 2003-10-08 2007-02-28 Harvard College PYROVALERON ANALOGUE AND ITS THERAPEUTIC APPLICATIONS
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7144868B2 (en) 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
EP1699459B1 (en) 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
DE102004009704A1 (de) 2004-02-27 2005-09-15 Dmitry Cherkasov Makromolekulare Nukleotidverbindungen und Methoden zu deren Anwendung
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
AU2005256963A1 (en) 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
ES2432113T3 (es) 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
US9035035B2 (en) 2004-11-05 2015-05-19 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
CN101072554A (zh) 2004-11-08 2007-11-14 坎-菲特生物药物有限公司 对于加速性骨再吸收的治疗
JP2006131596A (ja) 2004-11-09 2006-05-25 Univ Nagoya ヌクレオチド及びその誘導体の製造方法
EP1827460A4 (en) * 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
SI1848718T1 (sl) 2005-02-04 2012-12-31 Millennium Pharmaceuticals, Inc. Inhibitorji E1 aktivacijskih enzimov
WO2006094347A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
JP2006248949A (ja) 2005-03-09 2006-09-21 Univ Nagoya ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
CA2600359A1 (en) 2005-03-09 2006-09-09 Idenix (Cayman) Limited Nucleosides with non-natural bases as anti-viral agents
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
CA2609342A1 (en) 2005-04-26 2006-11-02 Andrei L. Gartel Nucleoside compounds and methods of use thereof
WO2007006544A2 (en) 2005-07-12 2007-01-18 Vrije Universiteit Brussel Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
EP1928475B1 (en) * 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
US8067391B2 (en) 2005-10-03 2011-11-29 University Health Network ODCase inhibitors for the treatment of malaria
EP1947092B1 (en) 2005-11-09 2015-04-15 Tosoh Corporation Method for producing nucleic acid base having perfluoroalkyl group
EP2010553A1 (en) 2006-04-03 2009-01-07 AstraZeneca AB Substituted adenines and the uses thereof
WO2007149554A2 (en) 2006-06-22 2007-12-27 The Johns Hopkins University Methods for restoring neural function
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
DE602007009998D1 (de) 2006-08-08 2010-12-02 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1-aktivierenden enzyme
DE102006037786A1 (de) 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
GB0618235D0 (en) 2006-09-15 2006-10-25 Lauras As Process
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
WO2008086042A2 (en) 2007-01-10 2008-07-17 Chisari Francis V Preventing infection by a measles or respiratory syncytial virus
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
US20120135091A1 (en) 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
EP2993473A1 (en) 2007-01-30 2016-03-09 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
KR20100014878A (ko) 2007-01-31 2010-02-11 앨리오스 바이오파마 인크. 2-5ａ 유도체, 및 항암제, 항바이러스제 및 항기생충제로서 이의 용도
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
JP2008214305A (ja) 2007-03-07 2008-09-18 Kotobuki Seiyaku Kk 置換アミン誘導体及びこれを有効成分とする医薬組成物
WO2008117046A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo [4, 3-d] pyrimidines as antibacterial compounds
WO2008117047A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
EP1980568A1 (de) 2007-04-13 2008-10-15 Eberhard Karls Universität Tübingen Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung
ES2530763T3 (es) 2007-06-25 2015-03-05 Anadys Pharmaceuticals Inc Procedimiento continuo de hidrólisis enzimática
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
ES2490606T3 (es) 2007-10-15 2014-09-04 Can-Fite Biopharma Ltd. Procedimiento para inducir proliferación de hepatocitos y usos del mismo
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
US20090181921A1 (en) 2007-12-21 2009-07-16 Alios Biopharma Inc. 2-5a analogs and their methods of use
JP5230755B2 (ja) 2008-02-22 2013-07-10 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−ｋｉｔおよびＰＤＧＦＲキナーゼ阻害剤としてのヘテロ環化合物および組成物
US8445669B2 (en) * 2008-04-10 2013-05-21 Hamari Chemicals, Ltd. Production process of ethynylthymidine compounds from 5-methyluridine as a starting material
WO2009126293A2 (en) 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
EP3042660A3 (en) 2008-04-15 2016-10-26 RFS Pharma, LLC. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
DE102008035299A1 (de) 2008-07-29 2010-02-04 Resprotect Gmbh Konjugat aus Hsp27 und einem Nukleosid, Verfahren zur Phosphorylierung von Hsp27 und Verwendung zur Herstellung eines Arzneimittels
GB0815315D0 (en) 2008-08-21 2008-09-24 Univ Leiden Organ protection
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
EP2332953A1 (en) 2008-09-05 2011-06-15 Kotobuki Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition comprising same as the active ingredient
WO2010030858A1 (en) 2008-09-15 2010-03-18 Enanta Pharmaceuticals, Inc. 4'-allene-substituted nucleoside derivatives
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010048552A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Methods of using oligomeric compounds comprising 2'-substituted nucleosides
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8609627B2 (en) 2009-02-06 2013-12-17 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2010101951A1 (en) * 2009-03-02 2010-09-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
AP2011005929A0 (en) 2009-03-20 2011-10-31 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs.
US20100240604A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
KR20120007077A (ko) * 2009-05-12 2012-01-19 써든 뤼서취 인스티튯 2'-플루오로아라비노뉴클레오시드들 및 그의 용도
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
KR101701510B1 (ko) 2010-07-09 2017-02-01 엘지이노텍 주식회사 발광소자
KR20200052384A (ko) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
JP5640552B2 (ja) 2010-08-23 2014-12-17 セイコーエプソン株式会社 制御装置、表示装置及び表示装置の制御方法
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012041965A1 (en) 2010-09-29 2012-04-05 Universidad Nacional De Quilmes Process for producing dialkylphosphotriesters of nucleosides by enzymatic transesterification and deprotection thereof for producing nucleoside monophosphates
US8580762B2 (en) 2010-12-03 2013-11-12 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
US8772474B2 (en) 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2012094248A1 (en) 2011-01-03 2012-07-12 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
AU2012290089B2 (en) 2011-08-01 2016-09-29 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
RU2672468C1 (ru) 2011-12-22 2018-11-15 Конекшис Лайф Сайенсиз Пвт. Лтд. Производные аза-адамантанов и их применение
SI2794600T1 (en) 2011-12-22 2018-03-30 Novartis Ag 2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis
MY173696A (en) 2011-12-22 2020-02-17 Connexios Life Sciences Pvt Ltd Cyclic amide derivatives as inhibitors of 11-beta- hydroxysteroid dehydrogenase and uses thereof
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
CA2866381C (en) 2012-03-13 2020-03-24 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
WO2013138210A1 (en) 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
PT2827875T (pt) 2012-03-21 2019-02-11 Janssen Biopharma Inc Nucleósidos substituídos, nucleótidos e análogos dos mesmos
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
KR20150027155A (ko) 2012-07-03 2015-03-11 브리스톨-마이어스 스큅 컴퍼니 바이러스 감염의 치료를 위한 뉴클레오시드 화합물의 부분입체이성질체적으로 풍부한 포스포르아미데이트 유도체의 제조 방법
WO2014022639A1 (en) 2012-08-01 2014-02-06 Vertex Pharmaceuticals Incorporated Solid forms of (4-isopropoxy-3-methoxyphenyl)(2'-methyl-6'-(trifluoromethyl)-3',4'-dihydro-2'h-spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]-1-yl)methanone
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
EA034342B1 (ru) 2012-09-04 2020-01-29 КАБУСИКИ КАЙСЯ ДиЭнЭйФОРМ Соединение, нуклеиновая кислота, вещество, несущее метку, и способ обнаружения
MX376762B (es) 2012-09-26 2025-03-07 Hoffmann La Roche Compuestos cíclicos éter pirazol-4-il-heterociclil-carboxamida y métodos de utilización.
BR112015006524A8 (pt) 2012-09-26 2019-08-20 Merck Patent Gmbh derivados de quinazolinona como inibidores de parp, seu processo de preparação, seu uso, medicamentos e conjunto (kit)
MX2015005500A (es) 2012-10-29 2016-02-09 Cocrystal Pharma Inc Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer.
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
HK1216535A1 (zh) 2012-12-21 2016-11-18 Alios Biopharma, Inc. 取代的核苷、核苷酸及其類似物
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
WO2014164533A1 (en) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
AR099632A1 (es) 2013-04-05 2016-08-10 Alios Biopharma Inc Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
WO2014209979A1 (en) 2013-06-26 2014-12-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015031763A2 (pt) 2013-06-26 2017-08-29 Alios Biopharma Inc Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN106573011A (zh) 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
BR112016029994A2 (pt) 2014-06-24 2017-08-22 Alios Biopharma Inc métodos de preparação de análogos de nucleotídeo substituídos
EP3171878A4 (en) 2014-07-22 2018-03-14 Alios Biopharma, Inc. Methods for treating paramyxoviruses
AU2015301334A1 (en) 2014-08-05 2017-02-23 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
US9981175B2 (en) 2014-09-12 2018-05-29 Dan DeLaRosa Taekwondo bag
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP2019524795A (ja) 2016-08-12 2019-09-05 ヤンセン バイオファーマ インク． 置換ヌクレオシド、ヌクレオチド、及びそのアナログ
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection

Also Published As

Publication number Publication date
US10464965B2 (en) 2019-11-05
SMT201800662T1 (it) 2019-01-11
PL2794627T3 (pl) 2019-04-30
JP2018188468A (ja) 2018-11-29
AR089408A1 (es) 2014-08-20
ECSP14010277A (es) 2015-08-31
EP3466959A1 (en) 2019-04-10
AU2012358803A1 (en) 2014-08-07
CN104114568B (zh) 2017-09-01
EA035493B1 (ru) 2020-06-25
EA201491040A1 (ru) 2015-01-30
JP6718487B2 (ja) 2020-07-08
MX2014007480A (es) 2014-07-30
US20210179656A1 (en) 2021-06-17
CL2014001641A1 (es) 2014-12-12
SG11201402826YA (en) 2014-12-30
IL272953B (en) 2021-10-31
PH12015502273A1 (en) 2017-12-11
UY34536A (es) 2013-07-31
HRP20182096T1 (hr) 2019-02-22
EP2794627B1 (en) 2018-09-26
BR112014014740A8 (pt) 2017-07-04
JP6385825B2 (ja) 2018-09-05
JP2015503506A (ja) 2015-02-02
CN104114568A (zh) 2014-10-22
ES2702060T3 (es) 2019-02-27
KR20140108287A (ko) 2014-09-05
HK1203076A1 (en) 2015-10-16
PH12014501436A1 (en) 2014-10-08
HUE041509T2 (hu) 2019-05-28
MX356509B (es) 2018-05-30
SG10201913554YA (en) 2020-03-30
TWI659963B (zh) 2019-05-21
US11021509B2 (en) 2021-06-01
IL272953A (en) 2020-04-30
US20200024297A1 (en) 2020-01-23
KR102072041B1 (ko) 2020-01-31
HK1203204A1 (en) 2015-10-23
CO6990737A2 (es) 2014-07-10
LT2794627T (lt) 2019-01-10
RS58099B1 (sr) 2019-02-28
CA2860289A1 (en) 2013-06-27
SG10201610936RA (en) 2017-02-27
US9073960B2 (en) 2015-07-07
AU2018203423A1 (en) 2018-06-07
SI2794627T1 (sl) 2019-02-28
IL233152B (en) 2020-03-31
AU2018203423B2 (en) 2020-04-30
CA3107640A1 (en) 2013-06-27
EP2794627A1 (en) 2014-10-29
PH12014501436B1 (en) 2014-10-08
IL233152A0 (en) 2014-07-31
AP2014007796A0 (en) 2014-07-31
BR112014014740A2 (pt) 2017-06-13
HK1248239A1 (zh) 2018-10-12
EP2794627A4 (en) 2015-04-29
AU2012358803C1 (en) 2019-12-19
CN107459544B (zh) 2021-03-16
PT2794627T (pt) 2018-12-19
DK2794627T3 (en) 2019-01-14
CN107459544A (zh) 2017-12-12
BR112014014740B1 (pt) 2021-08-24
US20130165400A1 (en) 2013-06-27
ZA201404486B (en) 2022-03-30
AU2012358803B2 (en) 2018-02-15
UA117095C2 (uk) 2018-06-25
CY1121416T1 (el) 2020-05-29
WO2013096679A1 (en) 2013-06-27
US20150315228A1 (en) 2015-11-05
GEP20166496B (en) 2016-06-27
TW201333027A (zh) 2013-08-16
NZ627179A (en) 2016-07-29
MX2018006658A (es) 2021-12-08

Similar Documents

Publication Publication Date Title
CA2860289C (en) Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections
CA2866901C (en) Substituted nucleosides, nucleotides and analogs thereof
US10485815B2 (en) Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) Substituted nucleosides, nucleotides and analogs thereof
HK1203143B (en) Substituted nucleosides, nucleotides and analogs thereof
NZ627179B2 (en) Substituted nucleosides, nucleotides and analogs thereof
HK1203076B (en) Substituted nucleosides, nucleotides and analogs thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171219